TRUST-II: a global phase II study of taletrectinib in <i>ROS1</i> -positive non-small-cell lung cancer and other solid tumors-Reference-Cited by-同舟云学术

TRUST-II: a global phase II study of taletrectinib in ROS1 -positive non-small-cell lung cancer and other solid tumors

Published:2023-01 Issue:2 Volume:19 Page:123-135
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncol.

Author:

Nagasaka Misako¹²^ORCID,Ohe Yuichiro³^ORCID,Zhou Caicun⁴,Choi Chang-min⁵,Yang Nong⁶^ORCID,Liu Geoffrey⁷,Felip Enriqueta⁸^ORCID,Pérol Maurice⁹,Besse Benjamin¹⁰^ORCID,Nieva Jorge¹¹^ORCID,Raez Luis¹²^ORCID,Pennell Nathan A¹³^ORCID,Dimou Anastasios¹⁴^ORCID,Marinis Filippo de¹⁵,Ciardiello Fortunato¹⁶,Seto Takashi¹⁷^ORCID,Hu Zheyi¹⁸,Pan Max¹⁸,Wang Weiqing¹⁸,Li Shuanglian¹⁸,Ou Sai-Hong I¹²^ORCID

Affiliation:

1. University of California Irvine School of Medicine, Orange, CA, USA

2. Chao Family Comprehensive Cancer Center, Orange, CA, USA

3. Department ofThoracic Oncology,National Cancer Center Hospital, Tokyo, Japan

4. Department of Medical Oncology,Shanghai Pulmonary Hospital,Tongji University School of Medicine, Shanghai, China

5. Department of Pulmonary and Critical Care Medicine,Asan Medical Center,University of Ulsan College of Medicine, Seoul, Republic of Korea

6. Department of Medical Oncology,Hunan Cancer Hospital,Xiangya School of Medicine,Central South University, Changsha, China

7. Department of Medical Oncology and Hematology,Princess Margaret Cancer Centre,University Health Network, Toronto, Canada

8. Vall d’Hebron Institute of Oncology,Vall d’Hebron University Hospital, Barcelona, Spain

9. Department of Medical Oncology,Léon Bérard Cancer Center, Lyon, France

10. Department of Cancer Medicine,Gustave Roussy Cancer Centre, Villejuif, France;Paris-Saclay University, Orsay, France

11. Division of Medical Oncology,Norris Comprehensive Cancer Center,University of Southern California, Los Angeles, CA, USA

12. Thoracic Oncology Program,Memorial Cancer Institute/Memorial Health Care System,Florida Atlantic University, Miami, FL, USA

13. Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA

14. Department of Oncology,Mayo Clinic, Rochester, MN, USA

15. European Institute of Oncology, IRCCS, Milan, Italy

16. Department of Precision Medicine,Division of Medical Oncology,University of Campania Luigi Vanvitelli, Naples, Italy

17. Precision Medicine Asia (PREMIA) Co. Ltd, Tokyo, Japan

18. AnHeart Therapeutics, NY, USA

Funder

consulting or advisory role

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.2217/fon-2022-1059

Reference14 articles.

1. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, version 2.2021;Ettinger DS;J. Natl,2021

2. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

3. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer

4. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer;Gainor JF;JCO Precis. Oncol.,2017

5. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of newly developed and validated UPLC-MS/MS method for pharmacokinetic study of ROS1/NTRK inhibitor taletrectinib in beagle dog plasma;Journal of Chromatography B;2024-09

2. Advances and future directions in ROS1 fusion-positive lung cancer;The Oncologist;2024-08-23

3. TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers;npj Precision Oncology;2024-08-08

4. Taletrectinib: TRUST in the Continued Evolution of Treatments for ROS1 Fusion–Positive Lung Cancer;Journal of Clinical Oncology;2024-08-01

5. Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study;Journal of Clinical Oncology;2024-08-01